Search Results: Endometrial Cancer (17 results)
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.
Study of an Investigational Drug, E7386 Plus Lenvatinib in People with Endometrial Cancer after Chemotherapy and Immunotherapy
https://www.facingourrisk.org/research-clinical-trials/study/355/study-of-a-new-drug-e7386-in-combination-with-lenvatinib-in-people-with-previously-treated-endometrial-cancer
Treatment
Treatment study for people with previously treated endometrial cancer
This trial will evaluate the optimal dose, safety and effectiveness of an investigational drug called E7386 given together with a targeted therapy called lenvatinib.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer
https://www.facingourrisk.org/research-clinical-trials/study/323/sexual-health-and-rehabilitation-online-shareonline-an-educational-intervention-for-young-women-after-cancer
Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes
SHAREonline compares two brief educational interventions conducted by videoconference to learn if they help women age 19-49 manage sexual function changes after cancer treatment.
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333/study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
The DETECT Study: Detecting Endometrial Cancer in Tampons
https://www.facingourrisk.org/research-clinical-trials/study/306/the-detect-study-detecting-endometrial-cancer-in-tampons
Prevention
Early detection of endometrial cancer in women undergoing hysterectomy surgery at the University of Alabama
This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer
Treatment
People with stage I endometrial cancer who are having a hysterectomy
This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.
Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer
https://www.facingourrisk.org/research-clinical-trials/study/301/registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer
Surveys, Registries, Interviews
Registry for people who screen for colorectal endometrial cancer
This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Treatment
This study is for people with recurrent endometrial cancer
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:
- have a tumor marker known as microsatellite stable (MSS), OR
- have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Self -Perception and Intimacy After the Cancer Experience (SPICE)
https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.
Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors
Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer
Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.
Cancer Experience Registry
https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer
https://www.facingourrisk.org/research-clinical-trials/study/192/restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer
People with stage 1-3 cancer
Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.
Additional Results on Clinicaltrials.gov Endometrial Cancer
175 results
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT ID: NCT06607185 (https://clinicaltrials.gov/study/NCT06607185)
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://clinicaltrials.gov/study/NCT06276491)
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT ID: NCT06855706 (https://clinicaltrials.gov/study/NCT06855706)
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT ID: NCT06463028 (https://clinicaltrials.gov/study/NCT06463028)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT06040970 (https://clinicaltrials.gov/study/NCT06040970)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT ID: NCT06989112 (https://clinicaltrials.gov/study/NCT06989112)
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT ID: NCT06538337 (https://clinicaltrials.gov/study/NCT06538337)
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT ID: NCT05705505 (https://clinicaltrials.gov/study/NCT05705505)
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://clinicaltrials.gov/study/NCT05646316)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
NCT ID: NCT07062016 (https://clinicaltrials.gov/study/NCT07062016)
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT ID: NCT06730347 (https://clinicaltrials.gov/study/NCT06730347)
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT ID: NCT05154487 (https://clinicaltrials.gov/study/NCT05154487)
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT ID: NCT06993844 (https://clinicaltrials.gov/study/NCT06993844)
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT ID: NCT06330064 (https://clinicaltrials.gov/study/NCT06330064)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04657068 (https://clinicaltrials.gov/study/NCT04657068)
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
NCT ID: NCT06366347 (https://clinicaltrials.gov/study/NCT06366347)
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://clinicaltrials.gov/study/NCT05559879)
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
NCT ID: NCT06518564 (https://clinicaltrials.gov/study/NCT06518564)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT ID: NCT06943521 (https://clinicaltrials.gov/study/NCT06943521)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT ID: NCT07186842 (https://clinicaltrials.gov/study/NCT07186842)
Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://clinicaltrials.gov/study/NCT03785288)
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT06974110 (https://clinicaltrials.gov/study/NCT06974110)
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT ID: NCT06533059 (https://clinicaltrials.gov/study/NCT06533059)
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://clinicaltrials.gov/study/NCT05542407)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://clinicaltrials.gov/study/NCT03968406)
GYNecologic Cancer-Related COGnitive Impairment
NCT ID: NCT06662435 (https://clinicaltrials.gov/study/NCT06662435)
Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://clinicaltrials.gov/study/NCT04570553)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT ID: NCT06973161 (https://clinicaltrials.gov/study/NCT06973161)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT ID: NCT05056077 (https://clinicaltrials.gov/study/NCT05056077)
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT ID: NCT04774419 (https://clinicaltrials.gov/study/NCT04774419)
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
NCT ID: NCT05761561 (https://clinicaltrials.gov/study/NCT05761561)
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT ID: NCT05799274 (https://clinicaltrials.gov/study/NCT05799274)
Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy
NCT ID: NCT07075731 (https://clinicaltrials.gov/study/NCT07075731)
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
NCT ID: NCT06975293 (https://clinicaltrials.gov/study/NCT06975293)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05919264 (https://clinicaltrials.gov/study/NCT05919264)
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT ID: NCT05997017 (https://clinicaltrials.gov/study/NCT05997017)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT ID: NCT06695845 (https://clinicaltrials.gov/study/NCT06695845)
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://clinicaltrials.gov/study/NCT05941507)
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
NCT ID: NCT07120945 (https://clinicaltrials.gov/study/NCT07120945)
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
NCT ID: NCT07227077 (https://clinicaltrials.gov/study/NCT07227077)
The Better, Harder, Faster, Stronger Study
NCT ID: NCT07220512 (https://clinicaltrials.gov/study/NCT07220512)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://clinicaltrials.gov/study/NCT04567771)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT ID: NCT05787587 (https://clinicaltrials.gov/study/NCT05787587)
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT ID: NCT03422198 (https://clinicaltrials.gov/study/NCT03422198)
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
NCT ID: NCT03675893 (https://clinicaltrials.gov/study/NCT03675893)
Activity Coaching During Pelvic Radiation Therapy
NCT ID: NCT06746428 (https://clinicaltrials.gov/study/NCT06746428)
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT ID: NCT06689956 (https://clinicaltrials.gov/study/NCT06689956)
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT ID: NCT07227168 (https://clinicaltrials.gov/study/NCT07227168)
Multimedia Aid for Genetic Testing in Gynecologic Oncology
NCT ID: NCT07084168 (https://clinicaltrials.gov/study/NCT07084168)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)
A Study of a Weight Loss Intervention in People With Endometrial Cancer
NCT ID: NCT06751589 (https://clinicaltrials.gov/study/NCT06751589)
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
NCT ID: NCT07220239 (https://clinicaltrials.gov/study/NCT07220239)
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT ID: NCT06952504 (https://clinicaltrials.gov/study/NCT06952504)
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
NCT ID: NCT05743517 (https://clinicaltrials.gov/study/NCT05743517)
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT ID: NCT05548296 (https://clinicaltrials.gov/study/NCT05548296)
Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://clinicaltrials.gov/study/NCT05349227)
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT ID: NCT06293898 (https://clinicaltrials.gov/study/NCT06293898)
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT ID: NCT04008797 (https://clinicaltrials.gov/study/NCT04008797)
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
NCT ID: NCT06625515 (https://clinicaltrials.gov/study/NCT06625515)
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
NCT ID: NCT05979610 (https://clinicaltrials.gov/study/NCT05979610)
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
NCT ID: NCT06128551 (https://clinicaltrials.gov/study/NCT06128551)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT ID: NCT05527184 (https://clinicaltrials.gov/study/NCT05527184)
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
NCT ID: NCT06409052 (https://clinicaltrials.gov/study/NCT06409052)
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
NCT ID: NCT04969315 (https://clinicaltrials.gov/study/NCT04969315)
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT ID: NCT07182149 (https://clinicaltrials.gov/study/NCT07182149)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT07029399 (https://clinicaltrials.gov/study/NCT07029399)
Diet, Hepcidin, and Chemotherapy RDI
NCT ID: NCT06483997 (https://clinicaltrials.gov/study/NCT06483997)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT ID: NCT06906341 (https://clinicaltrials.gov/study/NCT06906341)
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT ID: NCT05520099 (https://clinicaltrials.gov/study/NCT05520099)
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831 (https://clinicaltrials.gov/study/NCT05797831)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT ID: NCT05366881 (https://clinicaltrials.gov/study/NCT05366881)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT ID: NCT06760819 (https://clinicaltrials.gov/study/NCT06760819)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)
Endometrial Cell Collection With the PadKit
NCT ID: NCT06464107 (https://clinicaltrials.gov/study/NCT06464107)
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://clinicaltrials.gov/study/NCT04586959)
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)
Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://clinicaltrials.gov/study/NCT05712668)
A Study of XMT-1660 in Participants With Solid Tumors
NCT ID: NCT05377996 (https://clinicaltrials.gov/study/NCT05377996)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT ID: NCT07044336 (https://clinicaltrials.gov/study/NCT07044336)
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT ID: NCT05256225 (https://clinicaltrials.gov/study/NCT05256225)
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://clinicaltrials.gov/study/NCT04839614)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://clinicaltrials.gov/study/NCT05691504)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT ID: NCT04930159 (https://clinicaltrials.gov/study/NCT04930159)
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
NCT ID: NCT03538665 (https://clinicaltrials.gov/study/NCT03538665)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT ID: NCT06481592 (https://clinicaltrials.gov/study/NCT06481592)
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://clinicaltrials.gov/study/NCT06242470)
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT ID: NCT06515613 (https://clinicaltrials.gov/study/NCT06515613)
ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT ID: NCT06339827 (https://clinicaltrials.gov/study/NCT06339827)
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT ID: NCT04291612 (https://clinicaltrials.gov/study/NCT04291612)
Vaginal Fluid Collection for Detection of Endometrial Cancer
NCT ID: NCT06294886 (https://clinicaltrials.gov/study/NCT06294886)
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT ID: NCT05103683 (https://clinicaltrials.gov/study/NCT05103683)
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)
DESTINY-PANTUMOUR04
NCT ID: NCT07124000 (https://clinicaltrials.gov/study/NCT07124000)
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
NCT ID: NCT06677112 (https://clinicaltrials.gov/study/NCT06677112)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT ID: NCT06239194 (https://clinicaltrials.gov/study/NCT06239194)
SLV-154 Treatment of Metastatic Solid Tumors
NCT ID: NCT06771219 (https://clinicaltrials.gov/study/NCT06771219)
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT ID: NCT05827614 (https://clinicaltrials.gov/study/NCT05827614)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://clinicaltrials.gov/study/NCT05950464)
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://clinicaltrials.gov/study/NCT03564340)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://clinicaltrials.gov/study/NCT05902988)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://clinicaltrials.gov/study/NCT05554328)
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
NCT ID: NCT05683418 (https://clinicaltrials.gov/study/NCT05683418)
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
NCT ID: NCT06795009 (https://clinicaltrials.gov/study/NCT06795009)
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://clinicaltrials.gov/study/NCT03065062)
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
NCT ID: NCT06925724 (https://clinicaltrials.gov/study/NCT06925724)
Sentinel Node Biopsy in Endometrial Cancer
NCT ID: NCT04073706 (https://clinicaltrials.gov/study/NCT04073706)
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT ID: NCT06999187 (https://clinicaltrials.gov/study/NCT06999187)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT ID: NCT06710847 (https://clinicaltrials.gov/study/NCT06710847)
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT ID: NCT05640999 (https://clinicaltrials.gov/study/NCT05640999)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://clinicaltrials.gov/study/NCT06257264)
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://clinicaltrials.gov/study/NCT04196257)
HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT ID: NCT06686043 (https://clinicaltrials.gov/study/NCT06686043)
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT ID: NCT06218914 (https://clinicaltrials.gov/study/NCT06218914)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT ID: NCT06395519 (https://clinicaltrials.gov/study/NCT06395519)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://clinicaltrials.gov/study/NCT04486352)
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT ID: NCT06774963 (https://clinicaltrials.gov/study/NCT06774963)
Uterine Preservation Via Lifestyle Transformation
NCT ID: NCT05903131 (https://clinicaltrials.gov/study/NCT05903131)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://clinicaltrials.gov/study/NCT04683653)
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT ID: NCT06486441 (https://clinicaltrials.gov/study/NCT06486441)
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)
Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://clinicaltrials.gov/study/NCT04512144)
Weight Loss Management in Endometrial Cancer Survivors
NCT ID: NCT06877572 (https://clinicaltrials.gov/study/NCT06877572)
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT ID: NCT05611931 (https://clinicaltrials.gov/study/NCT05611931)
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT ID: NCT05758688 (https://clinicaltrials.gov/study/NCT05758688)
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT ID: NCT05797168 (https://clinicaltrials.gov/study/NCT05797168)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://clinicaltrials.gov/study/NCT03682289)
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
NCT ID: NCT06365905 (https://clinicaltrials.gov/study/NCT06365905)
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT ID: NCT06096688 (https://clinicaltrials.gov/study/NCT06096688)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://clinicaltrials.gov/study/NCT06129604)
Integrated Cancer Repository for Cancer Research
NCT ID: NCT02012699 (https://clinicaltrials.gov/study/NCT02012699)
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT ID: NCT07209449 (https://clinicaltrials.gov/study/NCT07209449)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT ID: NCT03452774 (https://clinicaltrials.gov/study/NCT03452774)
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT ID: NCT07109726 (https://clinicaltrials.gov/study/NCT07109726)
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT ID: NCT03832361 (https://clinicaltrials.gov/study/NCT03832361)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT ID: NCT06708429 (https://clinicaltrials.gov/study/NCT06708429)
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT ID: NCT05669430 (https://clinicaltrials.gov/study/NCT05669430)
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT ID: NCT07023731 (https://clinicaltrials.gov/study/NCT07023731)
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT ID: NCT07038369 (https://clinicaltrials.gov/study/NCT07038369)
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT ID: NCT06677190 (https://clinicaltrials.gov/study/NCT06677190)
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://clinicaltrials.gov/study/NCT05819892)
Avera Cancer Sequencing and Analytics Protocol (ASAP)
NCT ID: NCT05142033 (https://clinicaltrials.gov/study/NCT05142033)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://clinicaltrials.gov/study/NCT04469764)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.